Core Insights - ST Zhongzhu, established in 1994 and listed in 2001, operates in real estate and pharmaceuticals, with a diversified business model covering upstream and downstream sectors [1] Financial Performance - For Q3 2025, the company reported revenue of 433 million yuan, ranking 15th in the industry, significantly lower than the top competitor Aier Eye Hospital's 17.48 billion yuan and the industry average of 2.966 billion yuan [2] - The medical segment generated 196 million yuan, accounting for 64.66% of total revenue, while real estate development contributed 78.37 million yuan (25.88%) and pharmaceuticals and others contributed 28.08 million yuan (9.27%) [2] - The net profit for Q3 2025 was -30.73 million yuan, ranking 12th in the industry, far behind Aier Eye Hospital's 3.367 billion yuan and the industry average of 290 million yuan [2] Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 17.18%, an increase from 14.15% year-on-year, but still below the industry average of 46.74%, indicating lower debt pressure [3] - The gross profit margin for Q3 2025 was 19.54%, down from 21.92% year-on-year and below the industry average of 31.10%, suggesting a need for improved profitability [3] Management Compensation - The chairman, Chen Xu, received a salary of 86,000 yuan in 2024, while the president, Ma Hua, earned 450,500 yuan [4] Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.26% to 20,200, while the average number of circulating A-shares held per account increased by 1.28% to 82,700 [5]
ST中珠的前世今生：2025年Q3营收4.33亿排名行业末位，净利润亏损排名12/15
Xin Lang Cai Jing·2025-10-30 16:19